Kevin O’Brien Fehr is a pharmacologist managing since 1992 basic research and genetics studies conducted in Canadian companies and universities on behalf of GlaxoSmithKline. She has extensive contacts in the academic and biotechnology communities throughout the country and is actively working to attract funding from GlaxoSmithKline’s international sources for the support of Canadian researchers. She serves in an advisory capacity on several Boards of Directors, including the AllerGen Network of Centres of Excellence and the Canada Foundation for Innovation. After working for ten years at the Addiction Research Foundation of Ontario as a scientist and educator, she joined the staff of the Medical Liaison Service of Sandoz Canada. There, she spent five years acting as an interface between the company and the Canadian medical research community in the areas of psychiatry and neurology.